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Abstract 
Development of the retinal vasculature is based on highly coordinated signalling between different cell types of the retina, 
integrating internal metabolic requirements with external influences such as the supply of oxygen and nutrients. The developing 
mouse retinal vasculature is a useful model system to study these interactions because it is experimentally accessible for intra 
ocular injections and genetic manipulations, can be easily imaged and develops in a similar fashion to that of humans. Research 
using this model has provided insights about general principles of angiogenesis as well as pathologies that affect the developing 
retinal vasculature. In this review, we discuss recent advances in our understanding of the molecular and cellular mechanisms 
that govern the interactions between neurons, glial and vascular cells in the developing retina. This includes a review of 
mechanisms that shape the retinal vasculature, such as sprouting angiogenesis, vascular network remodelling and vessel 
maturation. We also explore how the disruption of these processes in mice can lead to pathology - such as oxygen induced 
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Retinal vasculature is arguably the most studied vascular bed 
in the entire body. It can be readily imaged in living patients 
with ever increasing technical sophistication, which is 
exploited in an expanding range of fields (Bajwa et al., 2015; 
Cheung et al., 2017). Furthermore, the developing mouse 
retinal vasculature has become a hugely successful model 
system to study the basic biology of vascular growth. In 
particular, the introduction of inducible genetic mouse 
models has opened up the study of signalling pathways 
involved in postnatal retinal vasculature development. This 
has potential translational value in many areas, as there are 
numerous human conditions affected by pathological 
angiogenesis (Coorey et al., 2012; Stahl et al., 2010b; Ye, 
2016). Through such models, our understanding of the 
cellular and molecular mechanisms driving angiogenesis and 
the development of the retinal vasculature has improved 
considerably in recent years. Similar inroads have also been 
made in understanding abnormal retinal vasculature 
development in pathologies such as familial exudative 
vitreoretinopathy (FEVR), retinopathy of prematurity (ROP) 
and oxygen induced retinopathy (OIR). Here we review the 
latest advances in understanding how this unique vascular 
network develops under physiological as well as pathological 
conditions.  
1.1 Anatomy during development 
The main function of the retinal vasculature is to 
metabolically sustain the inner part of the retina via a 
laminar meshwork of capillaries that permeates the neural 
tissue. In contrast, the outer retina (containing 
photoreceptors) is avascular and supplied by the choroidal 
vasculature, which is separated from the neural retina only 
by the retinal pigment epithelium (RPE). Direct 
vascularisation of the inner retina is an “invention” of the 
mammalian lineage and is not seen in lower vertebrates, 
where oxygen and nutrients are delivered to the inner retina 
by vitreal vessels (Chase, 1982). This evolutionary older 
design can still be found in mammals during embryonic 
development, but vascular remodelling later leads to 
regression of these transient vitreal vessels (called the 
hyaloid vasculature), whilst new vessels grow into the retina 
from the optic nerve head. These new vessels initially form a 
flat, primary plexus in the nerve fibre layer that subsequently 
sprouts into the retina, establishing a secondary, deeper 
plexus. 
 
In humans, hyaloid vasculature formation, its regression and 
most retinal vasculature development all occur in utero. The 
hyaloid vasculature originates from the central hyaloid 
artery, which is folded into the optic vesicle during optic 
fissure closure at around 6 weeks of gestation (WG) (Gray 
and Lewis, 1918). It runs from the centre of the optic disc 
through the vitreous to the posterior lens and eventually 
drains into choroidal veins (Fig. 1) (Anand-Apte and 
Hollyfield, 2010; Saint-Geniez and D’Amore, 2004). It 
consists of the hyaloid artery (HA), vasculosa hyaloidea 
propria (VHP), tunica vasculosa lentis (TVL) and pupillary 
membrane (PM). Branching of the hyaloid artery over the 
posterior lens surface forms the TVL. As the TVL expands 
around the anterior part of the lens, it forms the PM, 
eventually draining into choroidal circulation (Saint-Geniez 
and D’Amore, 2004). The VHP, also derived from the HA, 
branches from a more proximal position. Whilst initially 
sitting on the retina, the VHP gradually lifts off and joins the 
TVL close to the equator of the lens as the eye increases in 
size and subsequently does not anastomose with the retinal 
vasculature (Ito and Yoshioka, 1999). The regression of 
hyaloid vessels begins around 13 weeks of gestation (WG) 
(Zhu et al., 2000) and the concomitant formation of the 
primary plexus starts around 15 WG, emerging from an 
existing capillary ring at the optic nerve head and spreading 
across the inner surface of the retina (Provis, 2001) in four 
main lobes. The primary plexus reaches the retinal periphery 
nasally at 36 WG and temporally at around 40 WG (Gariano, 
2003; Provis, 2001). At 25-26 WG, deeper plexus 
components form by angiogenic sprouting from the primary 
plexus veins (Fruttiger, 2007; Hughes et al., 2000; Provis, 
2001). These sprouts penetrate into the retina and establish 
two laminar networks on either side of the inner nuclear 
layer (INL) (Gariano et al., 1994). Deeper plexus vessel 
growth occurs from the centre to periphery, in the same 
outward expanding manner as the primary plexus. Unlike 
the rest of the retina, the foveal zone remains completely 
devoid of vessels throughout development (Gariano and 
Gardner, 2005). Retinal vascularization is complete by 38-40 
WG, by which time the hyaloid system has also fully 
regressed (Duke-Elder, n.d.; Mann, 1950). 
   
In mice, retinal vasculature development unfolds in a similar 
way to humans, but begins postnatally. The first retinal 
vessels sprout from the optic nerve head around birth, 
forming an expanding network (the primary plexus) that 
reaches the periphery around postnatal day (P)7 (Fruttiger, 
2007). It consists of alternating, arterial-venous loops and is 
radially symmetrical (Fig. 2A). At P7 the deeper plexus starts 
Fig. 1 Anatomy of the hyaloid vasculature in the developing eye. The 
Hyaloid Artery (HA) emerges from the optic nerve head, branches 
over the posterior lens as the Tunica Vasculosa Lentis (TVL) and 
becomes the Pupillary Membrane (PM) anteriorly. The Vasa 





to grow from veins in the primary plexus, penetrating the 
retina and establishing a laminar network around the INL, as 
in humans (Stahl et al., 2010b). Deeper plexus development 
is completed in the third postnatal week, by which point the 
hyaloid vessels have fully regressed. During this period, 
some of the major radial veins in the primary plexus relocate 
into the deeper plexus via vascular network remodelling. 
Apart from the involvement of apelin signalling, the 
mechanisms underlying this process are not well understood 
(McKenzie et al., 2012). Unlike the veins, all the arteries 
remain in the primary plexus, which results in two distinct 
capillary beds (primary plexus and deeper plexus) that share 
an arterial supply but have different venous drainage (Fig. 
2B). Hyaloid vascular regression in mice also occurs 
postnatally with the VHP and TVL regressing sharply 
between P4 and P8, and the PM exhibiting a steady rate of 
regression (Ito and Yoshioka, 1999).  
 
2. Retinal astrocyte development 
2.1 Embryonic Origin 
Retinal vasculature development is closely linked to retinal 
astrocytes. These specialised glial cells are only found in 
species that possess a retinal vasculature and provide the 
foundation for retinal angiogenesis (Stone and Dreher, 
1987). In foveate species such as primates, astrocytes are 
only present in vascular regions and are devoid from 
avascular areas, as for example the fovea (Gariano et al., 
1996; Schnitzer, 1987). During development, retinal 
astrocytes invade the retina from the optic disc. Retinal 
astrocytes and optic nerve astrocytes both express the 
transcription factor PAX2, but the two cell types should be 
viewed as separate lineages because they have distinct 
embryonic origins. 
 
Prior to optic fissure closure, PAX2 is expressed in the ventral 
half of the optic vesicle and optic stalk (Nornes et al., 1990). 
As this region invaginates and forms the optic fissure, PAX2 
becomes excluded from the retina (Schwarz et al., 2000; 
Zhao et al., 2012). However, a population of PAX2 and Netrin 
1 positive cells remains at the junction between the optic 
cup and optic stalk which generate the optic disc; a small cuff 
of cells around the exiting retinal ganglion cell (RGC) axons 
(Dakubo, 2003; Zhao et al., 2012).  The morphogens sonic 
hedgehog (SHH) and bone morphogenetic protein (BMP) 7 
regulate PAX2 expression and are critical for correct fissure 
closure and optic disc formation (Morcillo et al., 2006; Sehgal 
et al., 2009; Yang, 2004; Zhao et al., 2012). At around 
embryonic day (E) 15 in mice, a subset of cells in the optic 
disc - immature retinal astrocytes - start expressing platelet 
derived growth factor receptor alpha (PDGFRA). SHH 
signalling might contribute to the induction of PDGFRA in 
these cells because it has been linked to PDGFRA expression 
and activation in other cells (Dakubo, 2003; Lin et al., 2014; 
Xie et al., 2001). Regardless, retinal astrocytes are the only 
astrocyte type in the central nervous system (CNS) that 
express PDGFRA (Mudhar et al., 1993; Tao and Zhang, 2014) 
and, therefore, the initiation of PDGFRA expression in retinal 
astrocytes can be viewed as the beginning of a distinct 
astrocyte lineage.  
2.2 Retinal invasion 
Immature retinal astrocytes start emerging from the optic 
disc into the retina (around E18 in mice) as elongated, 
spindle shaped cells populating the nerve fibre layer, where 
they eventually take on a stellate morphology as they 
mature (Fruttiger, 2002). Reciprocal interactions between 
the neuroretina and astrocytes are important throughout 
this process (Fig. 3A). RGCs secrete a ligand for PDGFRA, 
PDGFA, which promotes astrocyte proliferation and 
migration in a centrifugal fashion across the inner retinal 
surface towards the retinal periphery, creating a mesh-like 
network (Fruttiger et al., 1996). In mice, injection of 
PGDFRA-neutralizing antibody causes underdevelopment of 
the astrocyte network, whilst overexpression of the PDGFA 
gene leads to astrocyte hyperplasia (Fruttiger et al., 1996). 
Fig. 2 (A) The developing mouse primary plexus (at P5) is radially symmetric and can be divided into a proliferative zone at the growing edge and 
a remodelling zone more centrally. Arrowheads indicate tip cells, arrows show capillary free zones around arteries (labelled A, veins are labelled 
V). (B) Deeper plexus development leads to two vascular networks in the adult that share the same arterial supply but are drained either through 




Furthermore, Cre-mediated inactivation of PDGFRA almost 
completely ablates the retinal astrocyte population and 
subsequent retinal angiogenesis (Tao and Zhang, 2016).  
 
Immature retinal astrocytes migrate to the inner limiting 
membrane (ILM), which contains extracellular matrix (ECM) 
proteins. These proteins can serve as an adhesive substrate, 
may contain instructive signals for migrating cells and can 
regulate the availability of soluble growth factors (reviewed 
by Brown, 2011; S. H. Kim et al., 2011b). The importance of 
this ECM structure for retinal astrocyte development is 
illustrated by knock-out mice lacking laminin chains α1, or γ3 
and β2. In these animals, ILM formation is severely 
disturbed, leading to impaired passage and distribution of 
retinal astrocytes (Edwards et al., 2010; Gnanaguru et al., 
2013; Pinzón-Duarte et al., 2010).  Similarly, neural retina 
specific, genetic deletion of a key enzyme (UDP-glucose 6-
dehydrogenase, UGDH) for glycosaminoglycan synthesis also 
disrupts the ILM and abolishes retinal astrocyte migration 
into the retina; whereas astrocyte specific UGDH deletion 
does not (Tao and Zhang, 2016). Glycosaminoglycans are 
polysaccharide chains (such as heparin and heparan 
sulphate among others) that are covalently linked to 
proteins (forming proteoglycans) and play a key role in ILM 
assembly. Thus, the ILM disruption after neural UGDH 
deletion is probably a direct consequence of impaired 
glycosaminoglycan synthesis, whereas the failed astrocyte 
invasion is caused indirectly by the ILM abnormalities (Tao 
and Zhang, 2016). 
   
It has also been suggested that different PDGFA isoforms are 
differentially bound by glycosaminoglycans (Andrae et al., 
2013), which might be important for establishing PDGFA 
concentration gradients that guide retinal astrocyte 
migration towards the periphery. However, retinal 
astrocytes can migrate towards PDGFA-soaked beads in a 
retinal explant assay, irrespective of whether the long 
(heparin binding) or the short (not heparin binding) isoform 
of PDGFA  has been used (Tao and Zhang, 2016). This 
suggests the existence of a chemoattractive gradient of 
PDGFA that is independent of extracellular retention motifs 
in PDGFA. It is possible that retinal astrocytes self-generate 
such a gradient by acting as a PDGFA sink (e.g. via PDGFA 
internalisation). Oxygen - delivered by the developing retinal 
vasculature - might also influence this system as mutant 
mice that lack the hypoxia-inducible factor 1 alpha (HIF1A) in 
the peripheral retina display decreased expression of PDGFA 
and a hypoplastic astrocyte network (Nakamura-Ishizu et al., 
2012). 
 
3. Neural-vascular interactions 
3.1 Effects of retinal astrocytes on blood vessels 
The expanding network of retinal astrocytes – spreading 
between the ILM and the nerve fibre layer – is followed by 
vessels emerging from the optic disc, creating the primary 
plexus of the developing retinal vasculature. These vessels 
tightly interact with the template provided by the astrocytes, 
which express vascular endothelial growth factor A (VEGF) 
(Fruttiger, 2007; Pierce et al., 1996; Stone et al., 1995; West 
et al., 2005). VEGF expression stimulates blood vessel 
growth and is induced by physiological hypoxia in the retina 
prior to the development of retinal vasculature (Fig. 3). 
Astrocyte-derived VEGF is, therefore, an obvious candidate 
to mediate the close relationship between astrocytes and 
vessels in the retina. However, astrocyte specific deletion of 
VEGF has only minor effects on the developing vascular 
plexus (Scott et al., 2010; Weidemann et al., 2010), 
suggesting that the intimate relationship between retinal 
astrocytes and endothelial cells in the developing retinal 
vasculature is also based on other factors.  
 
Nevertheless, retinal astrocytes are crucial for vascular 
development, as illustrated by astrocyte-specific deletion of 
PDGFRA (see section 2.2), which prevents astrocyte invasion 
into the retina. Consequently, the development of blood 
vessels does not occur, except for a few vascular sprouts 
which closely align to stray astrocytes that fail to be 
genetically inactivated (Tao & Zhang, 2016). The close 
proximity to astrocytes, required by endothelial cells, 
indicates that the essential role of astrocytes in angiogenesis 
might be based on providing a physical growth substrate for 
Fig. 3 (A) Cell-cell signalling between RGCs, retinal astrocytes and 
developing vessels controls the development of retinal vasculature. 
PDGFA released by RGCs acts on astrocytes to promote proliferation 
and migration. VEGF and APLN produced by retinal astrocytes and 
VEGF produced by RGCs and other neural cells act on endothelial 
cells. In reverse, endothelial cells stabilise retinal astrocytes via LIF. 
Similarly, oxygen provided by the growing vasculature feeds back 
on VEGF expression from retinal astrocytes and other neural cells.  
SEMA3E restricts growth of the developing plexus to the nerve fibre 
layer. Endothelial derived PDGFB has chemoattractant and mitotic 
effects on pericytes, but might also influence retinal astrocytes 
(stippled arrow). (B) Increased VEGF expression in the hypoxic 
periphery and VEGF suppression in the vascularised centre, creates 
a hypothetical VEGF gradient (in blue) that guides tip cell migration 




the vessels. Indeed, astrocytes have been shown to express 
fibronectin – an ECM protein - ahead of growing vasculature 
(Uemura et al., 2006). Fibronectin and heparan sulphate 
synergistically bind VEGF to guide endothelial tip cell 
migration, and their genetic deletion impairs vascular 
migration (Stenzel et al., 2011). Furthermore, endothelial 
filopodial protrusions closely align to astrocytes via 
adhesions formed between fibronectin and α5β1 integrin 
(Stenzel et al., 2011; Uemura et al., 2006). R-cadherin-
mediated cell to cell adhesions formed between astrocytes 
and the endothelial filopodia (Dorrell et al., 2002; Gerhardt 
et al., 2003) have also been shown to stabilise vessel sprouts. 
However, when factors such as astrocyte derived fibronectin 
and heparan sulphate are ablated together (Stenzel et al., 
2011), or when R-cadherin is blocked (Dorrell et al., 2002), 
the resulting impairment in growth of the primary vascular 
plexus is not as dramatic as the phenotype seen when the 
astrocyte population is ablated from the developing retina 
(Tao and Zhang, 2016). This suggests that other, as yet 
unknown, but essential factors for retinal vasculature 
development are provided by the astrocyte template. 
 
3.2 Effects of blood vessels on retinal astrocytes 
In addition to the effects retinal astrocytes have on blood 
vessels, a reverse interaction also occurs, where the 
developing vessels impact on retinal astrocyte development 
by promoting their differentiation. In response to the 
arriving blood vessels, the astrocytes upregulate glial 
fibrillary acidic protein (GFAP), cease to proliferate and 
downregulate VEGF expression (West et al., 2005). 
Astrocytes in contact with vessels also downregulate the 
orphan nuclear receptor tailless (TLX), which is strongly 
expressed in more peripheral, immature astrocytes, and is 
required for their proliferation and migration into the retina 
(Miyawaki et al., 2004; Uemura et al., 2006). Suppressing 
vessel growth with a VEGF antagonist (aflibercept, also 
known as VEGF-Trap) prevents upregulation of GFAP and 
downregulation of VEGF, resulting in a denser retinal 
astrocyte network. This demonstrates the negative feedback 
effect of vessels on retinal astrocytes (Uemura et al., 2006). 
Oxygen, supplied by the developing vessel network, appears 
to be a factor that mediates the effects of vessels on 
astrocytes, since oxygen can regulate GFAP and VEGF 
expression in retinal astrocytes (West et al., 2005). 
Furthermore, deleting hypoxia inducible factor 2A (HIF2A) 
specifically in retinal astrocytes accelerates their 
differentiation and lowers their numbers, leading to reduced 
retinal vasculature development (Duan et al., 2014). 
 
Other factors mediating crosstalk between blood vessels and 
retinal astrocytes are leukaemia inhibitory factor (LIF) and 
apelin (APLN). Astrocytes secrete APLN, which stimulates 
production of LIF from endothelial cells via the endothelial 
receptor for apelin (APLNR, also known as APJ) (Sakimoto et 
al., 2012). The LIF receptor (LIFR) is expressed by the 
surrounding retinal astrocytes awaiting vascularisation. LIF 
then induces astrocytes to differentiate into a more mature 
state and thereby acts as an inhibitor of retinal astrocyte 
proliferation (Kubota et al., 2008). This feedback loop 
stabilises both astrocytes and blood vessels, since the vessels 
depend on the retinal astrocytes. LIF and APLNR knock-out 
mice both display a denser astrocyte and vessel network 
(Kubota et al., 2008; Sakimoto et al., 2012), demonstrating 
that the two networks are intrinsically linked (Fig. 3A).  
 
Another connection between retinal astrocytes and blood 
vessels could involve PDGFB, which is expressed by 
endothelial cells and normally targets developing pericytes 
expressing PDGFRB (see section 5.3). However, PDGFB can 
also activate PDGFRA on retinal astrocytes (Andrae et al., 
2008), and endothelial cells have therefore the potential to 
not only stimulate pericytes, but also to promote retinal 
astrocyte proliferation (stippled arrow in Fig. 3A). Although 
this interaction has so far not been experimentally verified, 
it further highlights the complexity of the feedback 
interactions that can occur between retinal astrocytes and 
blood vessels.  
3.3 Role of RGCs in regulating retinal vasculature 
development 
Although the presence of retinal astrocytes is indispensable 
for normal retinal vasculature development, neurons in the 
retina also influence the growing retinal vasculature. Given 
that neurons have a high metabolic requirement, they are 
prone to experience hypoxia, stabilise HIF1A and 
consequently express VEGF (Semenza, 2011). VEGF 
produced by neurons and Müller cells is the likely reason 
why astrocyte specific VEGF deletion causes no impairment 
in the retinal vasculature observed (Scott et al., 2010; 
Weidemann et al., 2010, see chapter 4.2). In fact, RGCs are 
crucial for normal retinal vasculature development, since in 
mutant mouse strains that lack RGCs, the primary plexus fails 
to develop, despite the presence of retinal astrocytes 
(Edwards et al., 2012; Ghinia et al., 2016; Sapieha et al., 
2008). The importance of RGCs lies in their ability to sense 
hypoxia in the developing retina. Succinate - an intermediate 
of the Krebs cycle - accumulates in the hypoxic retina, and its 
receptor, G protein-coupled receptor-91 (GPR91), is 
primarily expressed in RGCs (Sapieha et al., 2008). Through 
GPR91, RGCs sense changes in the neuronal metabolic 
demand prior to HIF1A stabilisation, and regulate the 
production of angiogenic growth factors so that vascular 
supply meets the demands of the neuroretina. This is further 
supported by experiments where knockdown of retinal 
GPR91 resulted in reduced retinal vascularisation (Sapieha et 
al., 2008). 
 
G protein-coupled receptor coagulation factor-like (F2RL1) 
has also been shown to be highly expressed in RGCs and 
promotes retinal vascularisation during development 
through its regulation of VEGF (Joyal et al., 2014). 
Furthermore, RGCs also produce the anti-angiogenic 
semaphorin 3E (SEMA3E), which prevents misdirection of 
the developing vasculature and limits the growth of the 
primary plexus to the nerve fibre layer (Fig. 3A) (Fukushima 
et al., 2011; J. Kim et al., 2011a, see section 4.2). Moreover, 
VEGF receptor 2 (VEGFR2) is highly expressed in the 
neuroretina during the first week after birth and mediates 
receptor mediated endocytosis of VEGF. Neurone-specific 
genetic deletion of VEGFR2 prevents VEGF endocytosis by 
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neuronal cells, leading to an excess of VEGF in the 
extracellular space. This leads to a delay in radial extension 
of the primary plexus and premature initiation of deeper 
plexus development, demonstrating that retinal neurons 
titrate VEGF levels to co-ordinate the development of the 
retinal vasculature (Okabe et al.,2014).   
 
4. Mechanisms of sprouting angiogenesis 
In the expanding primary plexus, angiogenesis can be 
particularly well observed. At the leading edge, short vessel 
sprouts expand into the avascular retina and then fuse with 
neighbouring sprouts, creating perfused loops. A reiterative 
process of loop formation creates a primitive plexus, which 
subsequently remodels into a hierarchical network (Fig. 2A). 
The emergence of such a complex structure from just two 
cell types - endothelial cells and mural cells - poses many 
conceptual challenges: How is the requirement for a 
continuous, lumenised endothelium compatible with 
directional migration of endothelial cells towards hypoxic 
parenchyma? Or how can individual endothelial cells “know” 
their position within the network to display specific 
behaviours; for example, at the growing plexus edge or in 
differentiating arteries or veins? In recent years, significant 
progress has been made towards a better understanding of 
the integrated cellular and molecular mechanisms that 
underpin some of the basic morphogenetic functionalities 
required for blood vessel development. In this section, we 
broadly discuss aspects that are relevant to the retinal 
vasculature; however, other reviews cover these topics 
more comprehensively (Jin et al., 2014; Marcelo et al., 2013; 
Potente et al., 2011; Potente and Carmeliet, 2017). 
4.1 The endothelial tip-stalk machinery 
A fundamental morphogenetic module in vascular network 
formation is the extension of vessel sprouts. This process 
requires differential behaviour of endothelial cells, 
depending on their location. Cells at the tip of the sprout are 
more motile and less proliferative in comparison to 
endothelial cells in the stalk (Gerhardt et al., 2003). It has 
been proposed that tip cells guide the direction of growth, 
sensing gradients of VEGF and other angiogenic factors 
(Adams and Eichmann, 2010; Carmeliet and Tessier-Lavigne, 
2005; Larrivée et al., 2009). In contrast, cells in the stalk 
proliferate and form the vessel lumen, sustaining sprout 
extension and perfusion (Fig. 4A). Endothelial tip cells 
display a different transcriptional profile to the trailing cells 
in the stalk (del Toro et al., 2010; Strasser et al., 2010), which 
is the basis of their differential behaviour. Furthermore, 
endothelial cells in the tip state supress the tip phenotype in 
adjacent endothelial cells via the Notch signalling pathway. 
Because individual cells can flip dynamically between tip and 
stalk phenotypes, a dynamic competition for the tip position 
ensues (Jakobsson et al., 2010). 
 
The Notch ligand Delta like 4 (DLL4) is central to the tip 
phenotype and can be viewed as a toggle switch that sets the 
tip/stalk state. It is expressed strongly in the tip state, 
activating NOTCH1 in adjacent cells, where it supresses DLL4 
transcription (Benedito et al., 2009). Experimental blocking 
of DLL4/NOTCH1 signalling (chemically or via gene deletion) 
reduces this inhibition of neighbouring cells, allowing more 
endothelial cells to enter the tip state, leading to increased 
branching in the primary plexus of the retinal vasculature 
(Hellström et al., 2007; Lobov et al., 2007; Suchting et al., 
2007) (Fig. 4A, C). The Notch mediated tip/stalk toggle 
mechanism is tightly integrated with VEGF signalling 
(reviewed by Blanco and Gerhardt, 2013; Simons et al., 2016; 
Thurston and Kitajewski, 2008). On the one hand, activation 
of VEGFR2 promotes the transcription of DLL4, and hence 
the tip state. On the other, endothelial cells in the tip state 
are more sensitive to VEGF than endothelial cells in the stalk 
state, because NOTCH1 activation downregulates the 
expression of VEGFR2/3 and upregulates VEGFR1 (Benedito 
et al., 2012; Siekmann et al., 2008; Zarkada et al., 2015). 
VEGFR1 can act as a VEGF antagonist due to its decoy 
receptor activity (Kappas et al., 2008; Kendall and Thomas, 
1993). Therefore, this mechanism dynamically favours the 
tip state at the leading edge of the growing plexus (where 
VEGF concentration is most likely highest) based on the 
position of cells, rather than the identity of cells.    
 
Tip cell chemotaxis towards a VEGF source requires a 
gradient of VEGF levels (Bentley et al., 2009; Blanco and 
Gerhardt, 2013). Although such a gradient has never been 
formally demonstrated in the retina, its existence is likely 
because VEGF mRNA expression is higher in the peripheral, 
not yet vascularised – and therefore hypoxic – retina, 
compared to the central, perfused retina, where oxygen 
supplied by the developing vessels suppresses VEGF 
expression (West et al., 2005). Furthermore, experimental 
manipulations that disturb this VEGF gradient - for instance 
intraocular injection of either VEGF or VEGF antagonist 
Fig. 4 (A) The tip/stalk phenotype in sprouting endothelial cells is 
mediated via VEGF, inducing VEGFR2/3 and DLL4 at the tip. 
Activated Notch acts via Notch-targeted transcription factors (NTs) 
by supressing DLL4 and VEGFR2/3, and inducing VEGFR1. This 
reduces sensitivity to VEGF and stabilises the stalk phenotype. 
BMP9/10 in the plasma acts via ALK1 on similar downstream 
targets (ATs) as Notch, and further promotes the stalk phenotype. 
Vascular hyper-sprouting (C) occurs when Notch or ALK1 signalling 
is blocked (favouring the tip phenotype). In contrast, hypo-sprouting 
(D) can be induced by excessive BMP9. It is also found in mice with 
loss of function mutations in the TGFB1 and WNT signalling 




(aflibercept) - cause filopodia to disappear from the leading 
vascular edge, and consequently vascular plexus expansion 
is reduced (Gerhardt et al., 2003; Ubezio et al., 2016). 
Moreover, extracellular VEGF distribution and availability is 
regulated by interactions with components of the 
extracellular milieu, such as fibronectin or 
glycosaminoglycans, via heparin binding domains in 
alternatively spliced exons of VEGF, which can influence 
retinal vascular development (Domigan and Iruela-Arispe, 
2014; Gerhardt et al., 2003; Rocha et al., 2014; Stalmans et 
al., 2002; Vempati et al., 2011; Wijelath et al., 2006).  
 
It has been widely assumed that filopodia on endothelial tip 
cells are used for sensing the distribution of angiogenic 
factors; analogous to filopodia on axonal growth cones 
sensing guidance cues. This is based on the fact that filopodia 
extend in the direction of vascular growth and become 
misdirected and shorter in response to disturbances of VEGF 
distribution (De Smet et al., 2009; Gerhardt et al., 2003). 
However, these observations do not prove a causal 
relationship between filopodia and tip cell guidance. In fact, 
more recent experiments in zebrafish from Gerhardt et al. 
have shown that, surprisingly, filopodia are dispensable for 
endothelial tip cell guidance. In these experiments, the 
growth and patterning of intersegmental vessels were not 
disturbed by abolishing filopodia (using a low dose of 
Latrunculin B, which prevents F-actin polymerisation). 
Nevertheless, tip cells were still able to create lamellipodia, 
which, under these circumstances, might act as mediators of 
guided angiogenesis (Phng et al., 2013; Wacker et al., 2014). 
 
Although the VEGF/Notch signalling, described above, can 
execute the binary decision making between the tip and 
stalk state at the very tip of the sprout, it is less obvious how 
this mechanism can be used to supress the tip state in more 
proximal stalk cells that are not in direct contact with DLL4 
expressing tip cells. Here, the recent discovery of a novel 
function of the TGF beta superfamily signalling pathway in 
angiogenesis can provide some explanation. Blocking 
BMP9/BMP10 signalling, or genetic deletion of ALK1 (which 
is part of the BMP receptor complex), increases the number 
of tip cells and leads to the same hyperbranching phenotype 
as Notch signalling inhibition in the retinal vasculature (David 
et al., 2008, 2007; Larrivée et al., 2012; Ricard et al., 2012; 
Tual-Chalot et al., 2014); demonstrating that BMP9/10 - 
ALK1 signalling normally suppresses the tip state in 
endothelial cells. In fact, ALK1 activates similar downstream 
target genes as NOTCH1 (such as HES1, HEY1, HEY2, JAG1, 
VEGFR1), which promote the stalk state (Larrivée et al., 
2012; Moya et al., 2012). Intriguingly, BMP9 and BMP10 are 
present at high levels in plasma, suggesting an elegant 
stabilisation mechanism for the more proximal, perfused 
portion of the sprout, where endothelial cells are directly 
exposed to plasma (Fig. 4A).   
4.2 Modulators of the endothelial tip-stalk state 
The integration of the Notch, VEGF and ALK1 signalling 
pathways provides the basic conceptual machinery for 
maintaining a continuous endothelium in a lumenised, 
growing stalk, whilst supporting tip cell chemotaxis and 
invasion into the parenchyma. In addition, there are many 
other factors and pathways that can modulate this signalling 
network; some of which directly modulate Notch activity. 
For instance, JAG1 (a weak Notch ligand) acts as a 
competitive DLL4 antagonist (Benedito et al., 2009). Further 
regulation is found at the level of the Notch downstream 
effector, the Notch intracellular domain (NICD), which is 
destabilised by the Notch-regulated ankyrin repeat protein 
(NRARP) to prevent sustained signalling (Phng et al., 2009). 
Moreover, sirtuin 1 deacetylase (SIRT1), which also 
destabilises NICD, is a further negative regulator of the tip 
state (Guarani et al., 2011). In addition, DLL4 expression can 
be suppressed by the semaphorin SEMA3E, which is secreted 
in the retina by RGCs (as mentioned above in section 3.3) 
(Fukushima et al., 2011; J. Kim et al., 2011a). Interestingly, 
the receptor for SEMA3E, plexin D1 (PLXND1), is induced by 
VEGF (Fukushima et al., 2011; J. Kim et al., 2011a), which 
means that this tip state suppression mechanism is most 
active in endothelial cells at the leading plexus edge, where 
VEGF levels are highest. Several other class-3 semaphorins 
can also suppress the tip state and inhibit endothelial cell 
migration, such as SEMA3A (Ochsenbein et al., 2016), 
SEMA3C (Yang et al., 2015) and SEMA3D (Aghajanian et al., 
2014; Hamm et al., 2016). At first sight, it might appear 
counterintuitive to have so many negative regulators of the 
tip state. However, it is important to put brakes on the tip 
state, otherwise sprouts would branch excessively and 
produce too dense a plexus.      
 
That being said, there are also positive regulators of the tip 
state. For example, the enzyme phosphofructokinase-
2/fructose-2,6-bisphosphatase 3 (PFKFB3) promotes the tip 
phenotype by stimulating glycolysis. PFKFB3 synthesizes 
fructose-2,6-bisphosphate, which is an allosteric activator of 
6-phosphofructo-1-kinase (PFK1), the rate limiting enzyme 
of glycolysis. Endothelial cells rely heavily on glycolysis, in 
particular when they are migrating. Genetic deletion or 
pharmacological inhibition of PFKFB3 consequently reduces 
angiogenic sprouting by impairing tip cell activity. 
Conversely, endothelial cells that overexpress PFKFB3 can 
outcompete wild type cells for the tip cell position (De Bock 
et al., 2013; Schoors et al., 2014). Remarkably, this 
competitive advantage is maintained even when these cells 
are handicapped by introducing NICD overexpression 
(mimicking a pro-stalk Notch signal), suggesting that reduced 
glycolysis in stalk cells may be a key outcome of Notch 
signalling (De Bock et al., 2013). 
  
Another example of a positive contributor to the tip state is 
neuropilin 1 (NRP1). Genetic deletion of NRP1 in endothelial 
cells reduces sprouting activity at the leading edge of the 
primary plexus, resulting in thickened sprouts, reduced 
branching and slower plexus expansion (Aspalter et al., 
2015) (Fig. 4D). Furthermore, in mosaic experiments (where 
NRP1 has been deleted only in some but not all endothelial 
cells), wild type cells outcompete NRP1 knock-out cells for 
the tip position (Aspalter et al., 2015; Fantin et al., 2013), 
implicating NRP1 as a promoter of the tip state. NRP1 loss-
of-function phenotypes have long been attributed to 
impaired VEGF or semaphorin signalling because of NRP1’s 
well known function as a VEGFR2 or PLXND2 co-receptor (Gu 
et al., 2003; Kawasaki et al., 1999). However, mice with a 
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mutated form of NRP1 that cannot bind VEGF, develop 
normally (Gelfand et al., 2014). In addition, semaphorins 
tend to suppress the tip state (as mentioned above), rather 
than promote it, which suggests that NRP1 contributes to tip 
cell signalling in the context of an alternative pathway.  
 
Indeed, besides VEGF and semaphorins, NRP1 can also bind 
transforming growth factor beta-1 (TGFB1) (Glinka and 
Prud’homme, 2008) and has been shown to regulate TGFB1 
mediated sprouting angiogenesis during CNS development 
(Hirota et al., 2015). Endothelial specific TGFB receptor 2 
(TGFBR2) knock-out mice show a hypobranching phenotype 
in the primary plexus of the retinal vasculature very similar 
to NRP1 knock-out mice (Allinson et al., 2012). Moreover, 
the same phenotype is caused by retinal astrocyte specific 
deletion of integrin αv or β8 (ITAGV or ITGB8), which has 
been linked to deficient integrin-mediated TGFB activation 
(Arnold et al., 2012; Hirota et al., 2011; McCarty, 2009). In 
summary, there are multiple lines of evidence linking TGFB1 
to a function that supports the tip state during retinal 
vasculature development. Furthermore, it is intriguing that 
TGFB1 and BMP9/10, which signal through two separate 
arms of the TGFB superfamily pathway (Pardali et al., 2010), 
appear to have opposite effects on the tip state. However, 
the molecular details of this, and how exactly NRP1 
influences the balance between the two signalling arms, are 
yet to be fully elucidated.  
 
The characteristic sprout thickening and reduced branching 
at the growing edge of the primary plexus is not only found 
in NRP1, TGFRB2, ITGAV and ITGB8 knock-out mice, but it is 
also displayed by mice lacking Norrin (also known as Norrie 
disease protein, NDP) (Xu et al., 2004). This factor is secreted 
by Müller cells and can signal via the canonical WNT 
signalling pathway (Xu et al., 2004). Endothelial cells in the 
retinal vasculature express a receptor complex, consisting of 
FZD4, LRP5 and TSPAN12, that can bind Norrin with high 
affinity. Deleting any one of the three genes that make up 
this receptor complex phenocopies Norrin knock-out mice, 
which demonstrates that all three components are needed 
for effective signalling. These knock-out phenotypes in the 
developing retinal vasculature imply that Norrin signalling 
normally promotes the tip state in endothelial cells, but the 
downstream signalling circuitry is not fully known. One 
potential link could be the transcription factor SOX17, which 
is induced by Norrin (Ye et al., 2009), repressed by Notch 
signalling, and contributes to angiogenic and tip cell 
functions (Lee et al., 2014; Ye et al., 2009). However, 
although endothelial specific SOX17 deletion in mice does 
lead to reduced branching in the retinal vasculature primary 
plexus, it does not cause the typical sprout thickening seen 
in Norrin signalling knock-out mice (Lee et al., 2014), 
suggesting involvement of other factors. Thus, despite the 
strikingly similar retinal vasculature phenotypes caused by 
defective TGFB1 and Norrin signalling, it so far not clear 
where these two pathways intersect. 
 
In humans, gene mutations in the Norrin signalling pathway 
have been linked to familial exudative vitreoretinopathy 
(FEVR) and account for 4 out of the so far 5 identified FEVR 
genes (NDP, FZD4, LRP5, TSPAN12), causing roughly half of 
all FEVR cases (reviewed by Gilmour, 2014). The hallmark 
clinical feature of FEVR is incomplete vascularisation of the 
retinal periphery during development. Correspondingly in 
mice, Norrin signalling mutations delay the expansion of the 
primary plexus. Whether and how the tip-stalk balance is 
affected in FEVR is not yet clear though, because the human 
retina is not as easily accessible to cellular imaging analysis 
as the mouse retina. Furthermore, the gene mutations in the 
50% of FEVR cases that are not based on Norrin signalling 
defects still need to be identified. In this context, it will be 
interesting to see whether the phenotype similarities 
between Norrin and TGFB signalling defects in mice 
(described above) bear out in humans via the discovery of 
novel FEVR genes in the TGFB signalling pathway. 
4.3 Deeper plexus development 
The tip/stalk concept, which explains very successfully a 
specific behaviour of endothelial cells, initially emerged from 
studying primary plexus development in the mouse retinal 
vasculature and, therefore, the roles of many genes are well 
characterised in primary plexus development. However, 
other aspects of retinal vascularisation - such as deeper 
plexus development, network remodelling and artery/vein 
differentiation - are less studied and, therefore, less well 
understood. Nevertheless, many of the signalling pathways 
acting in the tip/stalk machinery during primary plexus 
development also have a role in other vascular development 
processes. For instance, there is a strong overlap between 
primary and deeper plexus development in mice. Deleting 
the above-mentioned genes in the TGFB or Norrin signalling 
pathways (Norrin, FZD4, LRP5, TSPAN12, TGFBR2, NRP1, 
ITGAV or ITGB8) not only stunts the growth of the primary 
plexus, but also negatively impacts on the development of 
the deeper plexus. However, the severity of the phenotype 
in the two networks is different. Whilst the primary plexus 
displays thickened sprouts and reduced branching, overall 
network formation still proceeds, albeit at a slower rate. In 
contrast, deeper network development completely fails 
(Allinson et al., 2012; Hirota et al., 2015, 2011; Junge et al., 
2009; Xu et al., 2004; Ye et al., 2009) and only produces thick, 
club-like stumps that project from the primary plexus into 
the retina and do not branch sideways (Fig. 5).  
 
Fig. 5 (A) Deeper plexus development is initiated from veins in the 
superficial plexus. (B) Loss of function mutations in the TGFB1 and 
WNT signalling pathway stunts deeper plexus development and 
leads to the formation of vascular clumps in the superficial layers of 
the retina. RGCL: retinal ganglion cell layer, INL: inner nuclear layer, 




It is tempting to speculate that Norrin and TGFB signalling 
might play a specific role in guiding vessel sprouts into the 
deeper layers of the retina. Indeed, the fact that Norrin is 
produced by Müller cells, along which the initial sprouts 
extend into the retina, raises the possibility that it may act as 
an angiogenic guidance cue. However, this is unlikely 
because ectopic expression of Norrin from the lens in 
transgenic mice can rescue the Norrin knock-out phenotype 
(Ohlmann et al., 2005). Furthermore, endothelial cells that 
lack FZD4 – one of the five FEVR genes - are able to 
participate in the deeper plexus vascularisation in mosaic 
animals (where not all endothelial cells lack FZD4), 
suggesting that neighbouring wild type endothelial cells can 
largely correct the vascular migration defects of FZD4 knock-
out endothelial cells (Wang et al., 2012). This may be 
explained by the tip/stalk model, which predicts that in 
mosaic situations, wild type cells are selected for the tip 
position and are capable of driving angiogenesis. Since 
Norrin (and TGFB) signalling promote the tip state (as 
mentioned above), a complete lack of tip cells can explain 
the clumping phenotype seen in the full knock-outs.  
 
Why the deeper plexus is more dramatically affected than 
the primary plexus is not established and open to 
speculation. However, it is unlikely that the difference in 
phenotype severity is caused by a unique property of the 
deeper retina, because a similar phenomenon is also 
observed during vascular development in the brain. Here, 
loss of function mutations in the TGFB signalling pathway 
(Arnold et al., 2014; McCarty, 2009) or in the Norrin/WNT 
signalling pathway (Kuhnert et al., 2010; Zhou and Nathans, 
2014) cause pronounced clumps in vessels that penetrate 
the brain (topologically corresponding to the retinal deeper 
plexus), whereas vessels at the brain surface (topologically 
corresponding to the retinal primary plexus) are normal. 
Thus, it appears that Norrin and TGFB signalling defects still 
permit the emergence of some tip cells during the 
development of the retinal primary and the brain superficial 
plexus, whereas this appears not to happen in the vessels 
penetrating the retina or the brain. Perhaps the fact that the 
development of these penetrating vessels must be initiated 
from already quiescent and differentiated vessels (lacking tip 
cells at this stage) plays a role here. 
 
The question remains then; what factors guide angiogenesis 
towards the outer retina? Not surprisingly, the strongest 
candidate for guiding deeper plexus development so far is 
VEGF. Indeed, genetic deletion of VEGF - specifically from 
amacrine and horizontal cells - impairs deeper plexus 
formation (Usui et al., 2015). The authors of this study show 
that physiological hypoxia drives VEGF expression in 
amacrine cells, which is needed to establish a layer of vessels 
within the deeper plexus that are tightly associated with this 
cell type. As mentioned earlier in section 3.3, VEGF 
bioactivity is further modulated by VEGFR2 expressing 
neurons, endocytosing VEGF and acting as a VEGF sink. 
During retinal development, neuronal VEGFR2 expression is 
downregulated at around P7, allowing for a build-up of VEGF 
and triggering deeper plexus development (Okabe et al., 
2014). However, little is currently known about deeper 
plexus development beyond the role of VEGF, and it remains 
to be established whether there are any other factors 
needed to drive and/or guide angiogenesis; particularly with 
regards to how horizontally or perpendicularly oriented cell 
populations (such as amacrine, horizontal and Müller cells) 
contribute to the patterning of this network.     
 
Correct retinal vascularisation requires not only the 
stimulation of angiogenesis, but also the presence of 
negative control mechanisms. For example, the expression 
of VEGFR1 by retinal myeloid cells in the deeper retinal 
layers - upon stimulation by WNT signalling - antagonises 
VEGF and angiogenic branching during deeper plexus 
development (Stefater et al., 2011). Furthermore, 
photoreceptors and the retinal pigment epithelium (RPE) 
also express soluble VEGFR1 (Luo et al., 2013), meaning 
vessels do not normally grow beyond the outer plexiform 
layer, and the photoreceptor layer remains completely 
avascular. Moreover, SEMA3F, which has also anti-
angiogenic properties, is expressed in the same location 
(Buehler et al., 2013). Interestingly, the anti-angiogenic 
barrier of the outer retina is overcome in mice that lack the 
very low density lipoprotein receptor (VLDLR). In these 
animals, the deeper plexus vessels continue to grow until 
they reach the subretinal space. It has been shown that this 
is due to a deficiency in energy substrates in the 
photoreceptors, which leads to HIF1A stabilisation and VEGF 
upregulation (Joyal et al., 2016), illustrating that the 
avascularity of the outer retina can be breached with 
sufficiently strong stimuli. This mechanism might also be 
relevant in human disease, such as macular telangiectasia 
type 2 or age related macular degeneration, where retinal 
angiomatous proliferation (RAP) or choroidal 
neovascularisation (CNV) can lead to vessels invading the 
photoreceptor layer (Charbel Issa et al., 2013; Donati et al., 
2005; Dorrell et al., 2009). 
 
5. Network remodelling and maturation 
Angiogenic sprout and loop formation generate primitive 
networks, which are subsequently remodelled into 
structured, hierarchical vascular trees. This remodelling 
process is governed by two opposing forces: vessel 
regression and vessel stabilisation (reviewed by Korn and 
Augustin, 2015). Lack of perfusion, endothelial cell migration 
and endothelial cell apoptosis are all destabilising factors, 
whereas perfusion, endothelial-mural cell interactions and 
vessel maturity are important contributors towards vessel 
stabilisation. Newly formed, immature capillaries are 
unstable and can regress quickly; whilst larger, more mature 
vessels are better at withstanding destabilising forces (Fig. 
6A). However, what exactly constitutes a mature or an 
immature vessel is not well specified and depends on many 
factors. An easier distinction can be made between the 
angiogenic and quiescent state of vessels, with the former 
being characterised by the presence of endothelial tip and 
stalk cells in the angiogenic sprout; and the latter containing 
non-proliferative endothelial cells in stable, more proximal 
vessels sections (referred to by some authors as ‘phalanx 
cells’). However, it should be recognised that this quiescent 
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category comprises a wide spectrum of maturation stages 
influencing vessel stability.  
 
5.1 Vessel pruning through endothelial cell 
migration 
At the growing edge of the developing primary plexus, 
vessels are highly proliferative (Ehling et al., 2013), whereas 
the region towards the centre of the retina shows little 
proliferation (except in the main radial veins) and is 
dominated by remodelling of the newly generated primitive 
plexus (Fig. 2A). Although vessels are quiescent in this 
remodelling region, they are still unstable, and either 
differentiate into more mature vessels or are pruned. The 
regression of these vessels in the remodelling network is 
largely driven by the migration of endothelial cells into 
neighbouring vessel branches, leading to selective pruning of 
individual capillaries, and strengthening of adjacent ones 
(Fig. 6B-D). This type of remodelling has been observed in 
chick embryos during early development of the 
extraembryonic vasculature (le Noble et al., 2004). Other 
studies in zebrafish and mouse yolk sac have shown that 
endothelial cells can undergo lateral migration (movement 
along the vessel without detachment from the basement 
membrane) during pruning of functionally redundant 
vessels, in order to establish a more efficient network 
topology (Chen et al., 2012b; Kochhan et al., 2013; Udan et 
al., 2013). The contribution of this process to retinal 
vasculature remodelling has so far not been directly 
observed in vivo, but there is good indirect evidence (based 
on mapping the polarity of individual endothelial cells) 
suggesting that primary plexus remodelling is heavily based 
on endothelial cell migration (Franco et al., 2015).  
 
Two key factors controlling lateral endothelial cell migration 
within the remodelling plexus are blood perfusion (the 
presence of blood in the capillaries) and shear stress (the 
mechanical force exerted by the blood against the capillary 
wall). This has been shown in zebrafish brain, where a 
reduction in blood flow is cable of initiating pruning; whilst 
forcing blood through a vessel is preventative (Chen et al., 
2012b). Similarly, in the retinal vasculature, high flow leads 
to a change in endothelial cell polarity, causing endothelial 
cell migration from low-flow into high-flow segments. This 
leads to increased stability of the high-flow, and regression 
of the low-flow vessels (Franco et al., 2015). The influence of 
blood flow has also been demonstrated by intravitreal 
injection of the potent vasoconstrictor angiotensin II in 
developing mice (at P9), which causes widespread non-
perfusion and regression in the retinal vasculature (Lobov et 
al., 2011). Shear stress also induces the transcription of 
Krüppel-like factor 2 (KLF2), which is a pivotal component of 
the endothelial transcriptional response to blood flow 
(reviewed by Novodvorsky and Chico, 2014). KLF2 stabilises 
flow via the induction of vasodilators (endothelial nitric 
oxide synthase and C-natriuretic peptide) and the repression 
of vasoconstrictors (endothelin-1 and angiotensin-
converting enzyme); thereby promoting vessel dilation and 
perfusion (Dekker et al., 2005).      
5.2 Apoptosis driven vessel regression 
Along with lateral migration, network remodelling can also 
be driven by apoptosis in specific endothelial cells, leading to 
selective vessel regression. Evidence of this process in the 
developing retinal vasculature comes from a study 
demonstrating the presence of CD18 positive T-lymphocytes 
in remodelling regions of the retinal vasculature. 
Furthermore, treatment with antibodies against CD18 (a 
leucocyte adhesion molecule) or Fas ligand (a type-II 
transmembrane protein of the TNF family, which induces 
apoptosis through the binding of its receptor) increased 
network density, implying that T-lymphocyte induced 
apoptosis in endothelial cells contributes to network 
remodelling (Ishida et al., 2003). However, a more recent 
study found that apoptosis events are relatively rare during 
primary plexus remodelling, suggesting that they do not play 
a major role in the pruning of capillaries during early retinal 
vasculature development (Franco et al., 2015). Furthermore, 
in mice lacking both apoptosis effector proteins BAK and BAX 
in endothelial cells, remodelling of the primary plexus is 
normal, confirming that lateral endothelial cell migration is 
the main driver of vessel pruning in this system (Watson et 
al., 2016). In wild type mice, a low level of apoptosis can still 
be detected, predominately around arteries at P6. This could 
be linked to the high oxygen and low VEGF levels in the 
immediate vicinity of arteries (Claxton and Fruttiger, 2003), 
and the formation of the capillary free spaces around them 
(Fig. 2A). Remarkably, however, BAK/BAX knock-out mice 
appear to have normal capillary free spaces, despite 
complete suppression of endothelial apoptosis (Watson et 
al., 2016), indicating that capillary pruning around arteries is 
also primarily mediated via lateral migration.  
 
In contrast, regression of the hyaloid vasculature is markedly 
delayed in BAK/BAX knock-out mice, demonstrating that 
endothelial cell apoptosis can be an important end-point in 
vessel regression (Watson et al., 2016). Apoptosis seems to 
be particularly relevant when an entire network is removed, 
for example during hyaloid vasculature or pupillary 
membrane regression. Here, macrophages can induce 
localised endothelial cell death via the secretion of WNT7B, 
which causes flow stasis and subsequently endothelial cell 
Fig. 6 (A) Newly formed vessels are stabilised by differentiating into 
a quiescent and more mature state. However, angiogenic and 
quiescent vessels can both become unstable and regress. (B-D) One 
mechanism of vascular regression can occur via lateral migration of 
endothelial cells into adjacent branches (purple cells), which leads 
to the pruning of the vessel. The perfused vascular lumen is 




apoptosis along the entire vessel (Lobov et al., 2005). This 
process is coordinated by angiopoietin 2 (ANG2) (produced 
by pericytes), which not only stimulates WNT7B secretion 
from macrophages, but also predisposes endothelial cells to 
apoptosis (Rao et al., 2007).  
 
Hyaloid regression is also delayed in mouse pups that are 
reared in the dark or lack the melanopsin gene (OPN4). Such 
mice display reduced apoptosis in hyaloid vessels and 
primary plexus overgrowth, caused by raised VEGF levels in 
the eyes (Rao et al., 2013). How exactly light modulates VEGF 
levels in this system is not yet known, but it is clear that 
neurons in the retina play a major role in hyaloid regression. 
Evidence for this comes from mice with a neuron specific 
VEGFR2 ablation (mentioned previously in section 3.3 and 
4.3, Okabe et al., 2014). In these animals, VEGF 
sequestration by neurons (via VEGFR2 endocytosis) is 
reduced, and the resulting increase in vitreal VEGF 
antagonises apoptosis in the hyaloid. This phenotype can be 
corrected by simultaneously deleting VEGF in neurons, 
which brings VEGF back down to normal levels (Yoshikawa et 
al., 2016).      
 
Irrespective of whether vessels regress via lateral migration 
or apoptosis, they leave behind an empty, collapsed 
basement membrane sleeve (Ehling et al., 2013; el-Hifnawi 
et al., 1994; Scott et al., 2010). These “string” or “ghost 
vessels” (as they are sometimes referred to) are commonly 
used as a readout of ongoing vessel regression. In developing 
tissues they are present only transiently (Ashton and Pedler, 
1962; Scott et al., 2010), whereas in adults, they appear to 
persist for much longer - even at the capillary level (Brown 
and Thore, 2011; Powner et al., 2016) - possibly due to a 
different basement membrane composition in fully matured 
blood vessels. 
5.3 Vessel maturation 
Vascular regression is antagonised by vessel maturation; a 
process involving multiple interactions between mural cells 
(pericytes and smooth muscle cells) and endothelial cells 
(reviewed by Armulik et al., 2011 and Winkler et al., 2011). 
One of the first steps in this relationship is the recruitment 
of mural cells to nascent endothelial sprouts. Here, 
endothelial cell derived PDGFB acts as a chemoattractant 
and mitogen for mural cells, which express PDGFRB (Andrae 
et al., 2008). PDGFRB signalling also induces autocrine SHH 
signalling in mural cells, which further stimulates their 
motility and proliferation (Yao et al., 2014).  
 
In addition, DLL4 and serine/threonine kinase (AKT)1/2 
signalling in endothelial cells induces the expression of the 
Notch ligand, Jagged1 (JAG1), which promotes mural cell 
coverage (Kerr et al., 2016; Pedrosa et al., 2015). The 
corresponding receptor for JAG1 on pericytes is NOTCH3. 
Mice lacking this receptor show reduced pericyte and 
smooth muscle cell coverage in their retinal vasculature 
(Henshall et al., 2015; Kofler et al., 2015; Liu et al., 2010). 
Correspondingly, heterozygous NOTCH3 mutations in 
humans leads to progressive degeneration of smooth muscle 
cells in small arterial vessels of the brain, a disorder called 
cerebral arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) (Joutel, 2011). In the retina, 
CADASIL causes some detectable changes in the morphology 
of arterioles, but functional disturbances are minimal (Roine 
et al., 2006).  
 
Endothelial-mural cell signalling also occurs in the reverse 
direction, from mural cells to endothelial cells. For instance, 
mural cells limit endothelial cell numbers, which is illustrated 
by excessive proliferation of endothelial cells after 
experimentally disrupting pericyte recruitment in the retinal 
vasculature (Hellström et al., 2001; Kofler et al., 2015; Ogura 
et al., 2017). At first sight, angiopoietin 1 (ANG1) seems a 
plausible candidate for mediating the stabilising influence of 
pericytes. It is secreted by mural cells, and the activation of 
its receptor (TIE2) on endothelial cells promotes vascular 
maturation and stabilisation (Augustin et al., 2009; 
Saharinen et al., 2008). However, more recent evidence 
suggests a more complex role of the ANG/TIE signalling 
system in retinal vasculature development and maturation 
(reviewed by Eklund et al., 2016). This is illustrated by 
genetic deletion experiments in mice, which have shown 
that ANG1 is only needed during early embryogenesis for 
heart development. If ANG1 is deleted after E13.5, mice are 
viable and have a perfectly normal retinal vasculature 
(Jeansson et al., 2011). Furthermore, deleting TIE2 in 
endothelial cells after birth (using a tamoxifen-inducible Cre-
lox system), only delays primary plexus development, and 
has no obvious effects on vessel maturation or network 
remodelling of the retinal vasculature (Savant et al., 2015). 
 
In contrast, retinal vasculature development is more 
noticeably affected by deletion of ANG2, which causes 
abnormal and reduced angiogenesis in the primary plexus, 
complete failure of deeper plexus development and 
persistent hyaloid vasculature (Gale et al., 2002; Hackett et 
al., 2002). Mechanistically this phenotype is not yet fully 
understood. This is partly due to the complex nature of the 
ANG/TIE signalling system, which can stabilise or destabilise 
vessels, depending on context. For instance, ANG2 has long 
been known to inhibit TIE2 signalling (Augustin et al., 2009; 
Yancopoulos et al., 2000), but under certain conditions, it 
can also act as an agonist (Yuan et al., 2009). This context-
dependent activity is mediated by TIE1, which regulates 
ANG-induced trafficking of TIE2 (Korhonen et al., 2016; 
Savant et al., 2015). In adult mice, inflammation leads to the 
cleavage of the TIE1 extracellular domain, which turns ANG2 
into a destabilising force. Conversely, under baseline 
conditions – with functional TIE1 present – ANG2 acts as a 
TIE2 agonist and stabilises vessels (Kim et al., 2016). 
Inducible deletion of TIE1 at birth increases vessel regression 
and endothelial apoptosis in the developing primary plexus 
(D’Amico et al., 2014; Savant et al., 2015), which could be an 
indication of an ANG2 stabilising activity during retinal 
vasculature development. On the other hand, destabilising 
properties of ANG2 might also be needed for deeper plexus 
development, to reactivate the quiescent vessels in the 
primary plexus when deeper plexus sprouting is initiated. 
However, ANG2 can also signal TIE2 independently via the 
integrins αvβ3, αvβ5 and α5β1 (Eklund et al., 2016; Felcht et 
al., 2012), and whether the failure of deeper plexus 
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development in ANG2 knock-out mice is linked to abnormal 
integrin (see section 4.3) or TIE2 signalling is not yet known.    
 
An important downstream target of the ANG/TIE signalling 
system is the transcription factor, forkhead box protein O1 
(FOXO1); which regulates many genes associated with vessel 
remodelling, vascular destabilization, and endothelial cell 
proliferation and apoptosis (Augustin et al., 2009; Daly et al., 
2004). TIE2 activation leads to an AKT-driven 
phosphorylation of FOXO1, which is then excluded from the 
nucleus and thereby rendered inactive (reviewed by 
Eijkelenboom and Burgering, 2013). In endothelial cells, this 
state has been linked to vessel maturation and stabilization; 
whereas nuclear localisation of FOXO1 is associated with 
vascular destabilisation and reduced junctional stability, as it 
is typically seen under inflammatory conditions (Augustin et 
al., 2009; Kim et al., 2016; Korhonen et al., 2016; Taddei et 
al., 2008). Furthermore, a recent study found that FOXO1 
also influences retinal vasculature development, where it 
regulates the proliferation and metabolic activity of 
endothelial cells (Wilhelm et al., 2016). The study 
demonstrated that in the proliferative zone at the leading 
edge of the growing primary plexus (Fig. 1A), FOXO1 is 
phosphorylated – possibly mediated via VEGF and/or 
ANG/TIE signalling (Augustin et al., 2009; Simons et al., 2016) 
– and excluded from the nucleus. This prevents FOXO1 from 
antagonising the MYC proto-oncogene (MYC) (Eijkelenboom 
and Burgering, 2013), a transcription factor that normally 
promotes endothelial cell proliferation, growth, and 
metabolic activity. A de-repression of MYC via FOXO1 
nuclear exclusion, therefore, promotes endothelial cell 
proliferation (Wilhelm et al., 2016). In contrast, in the 
remodelling zone, FOXO1 is localised in the nucleus of 
endothelial cells, consistent with low endothelial cell 
proliferation in this zone. This also fits with the destabilising 
activity of nuclear FOXO1 under inflammatory conditions 
mentioned above, since endothelial cells are dynamic in the 
remodelling zone (see section 5.1). However, whether 
FOXO1 also contributes to stable, long-term quiescence and 
vessel maturation is not yet clear.   
5.4 Vascular differentiation 
An integral aspect of vessel maturation is the differentiation 
of newly formed vessels into different types of mature 
vessels, such as capillaries, arteries, and veins. The best 
understood system of vascular differentiation is the 
formation of the dorsal aorta and cardinal vein. These 
vessels are formed during early embryogenesis by a process 
called vasculogenesis, which is based on migrating 
endothelial precursors (angioblasts) that form cords and 
assemble vessels de novo. It is well established that the 
arterial/venous fate assignment of these migrating 
angioblasts is critically regulated by DLL4/Notch signalling 
(Kim et al., 2008; Quillien et al., 2014; Siekmann and Lawson, 
2007; Trindade et al., 2008).  
 
The DLL4/Notch signalling pathway is also needed in the 
retinal vasculature for artery formation. The primary plexus 
of developing retinal vasculature lends itself as a useful 
model system to study artery/vein differentiation, because 
of its well-defined radial symmetry of arterial-venous loops 
and its peripheral-to-central gradient of vessel maturation 
(Fig. 1A). However, it is not formed by vasculogenesis but by 
angiogenesis, which is based on the extension of existing 
blood vessels (Fruttiger, 2002). As previously discussed, DLL4 
is not only expressed by tip cells (see section 4.1), but is also 
found in arterial endothelial cells (Claxton and Fruttiger, 
2004). Blocking DLL4 causes a reduction in arterial 
differentiation in the developing primary plexus, in addition 
to hyper-sprouting (Ridgway et al., 2006). The link between 
DLL4 expression in tip and arterial endothelial cells is not 
understood; however, the recent finding that arteries are 
formed by migrating endothelial cells during angiogenesis is 
intriguing. This insight is based on live imaging studies on the 
zebra fish fin, and on genetic labelling experiments in mouse 
retinal vasculature; both of which show that some 
endothelial cells at the tip position move within the existing 
vascular network into arteries via lateral migration, where 
they contribute towards vessel formation (Xu et al., 2014). 
Thus, migrating endothelial cells appear to contribute to 
artery formation in both processes, vasculogenesis and 
angiogenesis.  
 
The SoxF family of transcription factors plays a crucial role 
for artery specific expression of DLL4 (Sacilotto et al., 2013). 
Furthermore, the SoxF protein SOX17 is highly expressed in 
arteries, and its genetic deletion in mice leads to impaired 
artery differentiation in the retinal vasculature – besides 
vascular hyper-sprouting (Corada et al., 2013), although this 
depends on the genetic background. The related SOXF family 
members SOX7, SOX17 and SOX18 can have redundant 
functions and combined inactivation of SOX7, SOX17, and 
SOX18 leads to an almost complete loss of radial arteries, 
irrespective of the background (Zhou et al., 2015). SOX17 is 
strongly induced by Norrin/WNT signalling, thus linking WNT 
and Notch signalling in artery specification and 
differentiation (Corada et al., 2014, 2013). As previously 
discussed (see section 4.3), Norrin/WNT has also been 
implicated in regulating the endothelial tip state and deeper 
plexus development in retinal vasculature. Interestingly, this 
signalling axis also has a third function in retinal vasculature 
development: driving the differentiation of vascular barrier 
properties in the brain (reviewed by Engelhardt and Liebner, 
2014; Obermeier et al., 2013) and the retina (Wang et al., 
2012; Zhou et al., 2014). 
 
6. Oxygen-induced retinopathy (OIR) and 
retinopathy of prematurity (ROP) 
During brain development, the brain’s vasculature 
continuously grows to keep up with the steadily increasing 
brain volume. In comparison, retinal vascularisation is 
established more rapidly, when the metabolic supply for the 
retina switches from the hyaloid vasculature to the emerging 
retinal vasculature. A completely new network must be 
generated for a pre-existing, not yet vascularised but 
metabolically demanding tissue. Hence, the development of 
the retinal vasculature is uniquely sensitive to disturbances 
in angiogenesis and homeostasis. In humans, most retinal 
vasculature development is completed by birth (see section 
1.1), but in preterm infants, external (such as increased 
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oxygen concentrations) or internal influences (such as 
metabolic changes) can disturb retinal vasculature 
development and lead to ROP. In mice or rats, the retinal 
vasculature develops after birth, providing an accessible 
model system to study pathology in retinal vascular 
development.   
6.1 Mechanistic insights from the OIR model 
Oxygen, supplied by the developing retinal vessels, 
downregulates VEGF expression and shapes network 
development. This is illustrated by the capillary free spaces 
around arteries (Fig. 1A), where oxygen diffusion through 
the arterial wall into surrounding tissue prunes immature 
capillaries (see section 5.2). When mouse pups are exposed 
to increased atmospheric oxygen, tissue oxygenation can 
rise substantially via physically dissolved oxygen in plasma, 
independently of haemoglobin (which is already saturated). 
This is exploited in a popular OIR model (the "Smith model", 
Smith et al., 1994), where mouse pups are placed in 75% 
oxygen from P7 to P12 in order to induce an extreme form 
of capillary regression, which leads to a capillary free central 
retina. On return to room air (at P12), the resulting relative 
hypoxia triggers neovascularisation, which peaks at around 
P17 in severity and then spontaneously resolves by around 
3-4 weeks after birth. The main vascular pathology in this 
model manifests itself in the form of vascular tufts, that 
penetrate the inner limiting membrane and grow towards 
the vitreous. This feature is widely used as a model for 
pathological angiogenesis in the retina (Connor et al., 2009; 
Stahl et al., 2010b).  
 
There are several variations to the original “Smith model”, 
including an earlier readout based on artery tortuosity (Scott 
et al., 2014) or altered hyperoxia schedules; 80% oxygen for 
22 hours a day from P0-11, for example (Fletcher et al., 
2010b). Alternatively, switching between 50% and 10% 
oxygen every 12 hours can be applied from birth till P14 
(Penn et al., 1994), resulting in different vascular phenotypes 
compared to the original OIR model. A more severe 
pathology that persists into adulthood is induced by 
exposing mice to hyperoxia at P0 for one or two weeks, 
resulting in retinal degeneration, scarring and detachment; 
culminating in a 50% reduction in retinal function and a 
persistent and hyperplastic hyaloid (Lajko et al., 2016; 
McMenamin et al., 2016).  
 
A common feature of all OIR models is an initial, vessel-
depleting phase and a second, neovascular phase. The 
mechanisms underlying the former are less well understood 
than the latter, however, it has been shown that 
experimental manipulations that stabilise vessels during the 
first phase indirectly affect the second phase by reducing the 
ensuing tissue hypoxia. Mice lacking prolyl hydroxylase 1 
(PHD1, mediating degradation of HIFs), for example, show 
reduced vaso-obliteration during hyperoxia, a phenotype 
accompanied by increased VEGF levels (via HIF1A 
stabilisation) which aids vessel survival and leads to less 
severe neovascularisation (Huang et al., 2011a). Curiously, a 
second study found the same outcome in PHD2 knock-outs, 
but not in PHD1/PHD3 double knock-out mice (Duan et al., 
2011). Systemic administration of a blocker that targets all 
three PHDs (dimethyloxaloylglycine, DMOG) also reduces 
vaso-obliteration during hyperoxia (Sears et al., 2008; 
Trichonas et al., 2013), but surprisingly, this effect seems to 
be driven by HIF stabilisation in the liver, independent of 
VEGF (Hoppe et al., 2016, 2014). Another factor that may 
destabilise immature retinal vessels is vasoconstriction, as it 
was shown that blockers of vasoconstriction (losartan or 
captopril) can prevent vessel-obliteration during the 
hyperoxic phase (Lobov et al., 2011). However, a 
comprehensive picture of the mechanisms responsible for 
the loss of vessels during phase one of the OIR model still 
needs to be established. 
 
In contrast, neovascularisation (in the second phase) is a 
better understood outcome of OIR models. Here, the 
mechanisms that govern sprouting angiogenesis during 
normal retinal vascularisation (see chapter 4) provide a 
useful framework for understanding the causes of this 
vascular pathology. Not surprisingly, VEGF is critical. After 
the switch from hyperoxia to room air at P12 (as in the 
“Smith model”), the resulting hypoxia in the inner retina 
leads to pathologically high VEGF levels that prevent the 
tip/stalk selection machinery from working properly 
(Bentley et al., 2009; Gerhardt et al., 2003). Reducing VEGF 
levels from P12 onwards (e.g. with aflibercept or by genetic 
means) abrogates neovascular tufts and promotes normal 
angiogenesis, regenerating vessels in the previously capillary 
free regions (Huang et al., 2011b; Tokunaga et al., 2014; 
Weidemann et al., 2010). Similarly, hyperoxia treatment at 
P17 reduces VEGF levels and causes regression of 
neovascular tufts (Liu et al., 2013). The role of excessive 
tissue hypoxia is also illustrated in mutant mice with 
abnormally thin retinas (due to a mutation that causes 
perinatal photoreceptor degeneration). When these animals 
are put through the OIR protocol, oxygenation from the 
choroidal vasculature is sufficient to prevent excessive VEGF 
production, and the retinal vasculature regenerates 
normally without the formation of neovascular tufts (De 
Gooyer et al., 2006; Scott et al., 2014). Besides alterations to 
VEGF levels, there are several modulators of the tip/stalk 
machinery (see section 4.2) that can also influence 
neovascularisation in the OIR model; including intra-ocular 
injections of SEMA3E/A/C, which can prevent neovascular 
tuft formation (Fukushima et al., 2011; Joyal et al., 2011; 
Yang et al., 2015) and BMP9 which reduces 
neovascularization (Ntumba et al., 2016). On the other hand, 
Norrin/WNT signalling seems to promote pathological 
vascular growth in the OIR model, since blocking this 
pathway alleviates OIR pathology (Chen et al., 2011; 
Ohlmann et al., 2010). 
 
In addition to the well-known components of sprouting 
angiogenesis (see chapter 4), there are many other factors 
that can modulate vascular behaviour in OIR (Cavallaro et al., 
2014). For instance, insulin-like growth factor (IGF1) appears 
to facilitate retinal angiogenesis, since IGF1 knock-out mice 
exhibit delayed retinal vascularisation, despite normal VEGF 
levels (Hellstrom et al., 2001); and blocking or deleting IGF1 
receptor reduces neovascularisation in the OIR model 
(Kondo et al., 2003; Smith et al., 1999). Erythropoietin (EPO) 
is another factor that can modulate the vasculature in OIR. 
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During the first (vaso-obliterative) phase of OIR, 
administration of EPO protects retinal vessels; whilst during 
the second stage, exogenous EPO worsens neovasculari-
sation and reducing endogenous EPO alleviates it (Chen et 
al., 2009, 2008). Furthermore, nutrition also has a role in the 
prevention of vascular pathology in OIR. This is 
demonstrated by mouse studies showing that increased 
dietary intake of omega 3 polyunsaturated fatty acids has a 
protective effect against neovascularisation in OIR (Connor 
et al., 2007). This process is mediated via an induction of 
peroxisome proliferator activated receptor gamma (PPARG) 
and adiponectin (APN) (Fu et al., 2015; Sapieha et al., 2011; 
Stahl et al., 2010c). 
 
Many of the known factors that modulate vessel behaviour 
during OIR probably affect the vasculature indirectly through 
retinal glia or inflammatory cells. For example, the protective 
effects of angiotensin receptor blockers in OIR (reviewed by 
Fletcher et al., 2010a) are likely due to the prevention of 
retinal astrocyte loss, rather than a direct effect on the 
vessels themselves (Downie et al., 2008). Intravitreal 
injection of LIF, meanwhile, reduces vascular pathology in 
OIR via the growth stabilisation of retinal astrocytes, which 
express the receptor for LIF (see section 3.2 and Kubota et 
al., 2008); whilst intravitreal injection of astrocytes and 
astrocyte conditioned media in OIR rescues both 
endogenous astrocytes and microglia from hypoxic 
degeneration and reduced neovascularisation (Dorrell et al., 
2010). Retinal astrocytes can work synergistically with 
microglia to mediate inflammatory damage by producing 
inflammatory cytokines and chemokines, which recruit 
myeloid derived inflammatory cells (de Hoz et al., 2016). 
Furthermore, resident microglia and invading monocytes 
have also been shown to be modulators of the neovascular 
response in mouse OIR (reviewed in Scott and Fruttiger, 
2010).      
 
It is also possible to modulate the neovascular response in 
OIR indirectly by manipulating hypoxia sensing or metabolic 
homeostasis in the entire retina. This can be achieved by 
interfering with the hypoxia sensing mechanisms in retinal 
cells (as with the experiments targeting phase 1 of the OIR 
described above). Several compounds that can antagonise 
HIF1A have also been shown to reduce neovascularisation 
after intraocular injection in OIR (Jo et al., 2014; Park et al., 
2014; Yoshida et al., 2010; Zeng et al., 2017), as has Müller 
cell specific HIF1A deletion (Lin et al., 2011). Deleting HIF2A 
in retinal astrocytes also reduces neovascularisation, but 
interestingly HIF1A deletion does not (Weidemann et al., 
2010). Apart from sensing oxygen levels, retinal cells can also 
use the concentration of metabolic intermediates to 
respond to changes in vascular supply. During the second, 
hypoxic phase in the OIR model, aerobic respiration is 
reduced and the Krebs cycle intermediate, succinate, builds 
up. RGCs respond to succinate build-up (via GPR91, see 
section 3.3) by upregulating angiogenic factors, including 
VEGF, contributing to neovascularisation (Sapieha et al., 
2008). Thus, manipulating metabolic sensing or activity in 
the retina could also be a promising strategy to reduce 




6.2 Clinical translation from OIR models to ROP 
First described in 1942 (Terry, 1942), ROP is a widely 
recognised, but potentially avoidable vitreoretinopathy 
affecting pre-term infants (Blencowe et al., 2013; William A 
Silverman, 1980). It is a vision-threatening disease in which 
abnormal vascular development occurs at the leading edge 
of the developing primary plexus (Blencowe et al., 2013; 
Good et al., 2005). The initial clinical observation in humans 
is a thin demarcation line (stage 1), appearing at the 
boundary between the vascularised and avascularised 
peripheral retina. This line can develop into a white or pink 
ridge (stage 2), from which neovascular vessels can start to 
grow (stage 3), which in turn can then lead to partial (stage 
4) or full retinal detachment (stage 5). In addition, ROP 
classification also distinguishes three different geographical 
zones in which the pathologies occur, with the zone I being 
the most central and zone III the most peripheral. Signs of 
severe ROP include venous dilation and arteriolar tortuosity. 
If this is present in at least two quadrants, then the 
designation “plus” (+) is applied (International Committee 
for the Classification of Retinopathy of Prematurity, 2005). 
  
The underlying pathobiological mechanisms of ROP 
(reviewed by Hartnett and Penn, 2012) have been elucidated 
by studies using OIR models in mice, rats and cats. Some of 
the insights gained in these model systems have directly led 
to advancements in the management of human ROP. For 
instance, in the early 1950s, Norman Ashton demonstrated 
through his work on kittens that high atmospheric oxygen 
during retinal vasculature development can lead to vascular 
regression, and that subsequent withdrawal of atmospheric 
hyperoxia can trigger hypoxia in the retina, leading to an 
excessive neovascular response (Ashton et al., 1954). The 
translation of that insight into the clinic has led to a much 
more careful and controlled use of oxygen supplementation 
in preterm infants, compared to the 1950s. It also led to the 
application of laser photocoagulation for treating 
pathological neovascularisation (stage 3) in ROP, which is 
still the gold-standard treatment (Mutlu and Sarici, 2013; 
Pertl et al., 2015). It works by ablating parts of the retina 
where neovascularisation is the highest, alleviating excessive 
hypoxia (and VEGF production) and allowing for normal 
vascularisation to continue in other parts of the retina 
(Rivera et al., 2011). The major drawback of this treatment is 
the permanent loss of vision at ablation sites (Mintz-Hittner 
et al., 2011; Pertl et al., 2015).  
 
Furthermore, studies of the dynamics and the effects of 
VEGF expression in OIR animal models (see section 6.1) have 
led to numerous human trials evaluating the effectiveness of 
anti-VEGF agents in the treatment of ocular neovascular 
disease, including ROP. The BEAT-ROP study, a randomised 
controlled trial which compared anti-VEGF treatment to 
laser therapy (Mutlu and Sarici, 2013; Pertl et al., 2015), 
showed that intra-vitreal injection of bevacizumab (an 
antibody against VEGF) caused a statistically significant 
decrease in ROP recurrence in zone I, stage 3+ compared to 
laser therapy (42% vs 6%), but found no difference for zone 
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II, stage 3+ disease (Mintz-Hittner et al., 2011). Another 
smaller randomised controlled trial showed an increased 
rate of recurrence of ROP in zone II stage 3+ disease 
compared to laser therapy, but also showed that in most 
cases recurrent ROP regressed with another anti-VEGF 
injection (Karkhaneh et al., 2016). These studies contradict 
reports in the literature (Dorta and Kychenthal, 2010; Mintz-
Hittner and Kuffel, 2008; Tahija et al., 2014; Wu et al., 2011), 
which suggest a uniform benefit of bevacizumab in both 
zone I and II. However, concerns regarding the systemic 
effects of these drugs - especially on the vessels of 
developing organs like the brain, lungs and kidneys - remain 
unaddressed, due to the short follow-up period of these 
studies (Pertl et al., 2015). The CARE-ROP trial (Clinical Trials 
Identifier: NCT02134457) aims to address some of these 
concerns, whilst also aiming to establish the efficacy of half-
dose treatment.  
 
To avoid the potential side effects of anti-VEGF agents, 
several other factors and signalling pathways have been 
proposed as possible targets for ROP management. None of 
these have yet been tested in phase 3 trials, but several 
phase 1/2 trials have been started or completed. From such 
a trial, it has been suggested that blockers of beta-adrenergic 
receptors may be useful in ROP, based on their efficacy in 
model systems and in treating infantile haemangioma 
(reviewed by Casini et al., 2014). Although there are some 
conflicting results from studies in the mouse OIR model (J. 
Chen et al., 2012; Filippi et al., 2012), data from early phase 
trials suggests some efficacy in ROP (Bancalari et al., 2016; 
Filippi et al., 2013).   
 
Another example of ongoing efforts to translate efficacy in 
OIR models into the clinic, is the targeting of the IGF1 
signalling pathway (see section 6.1). Proof of concept 
experiments in animals have been mirrored by observations 
in humans, with premature babies showing lower than 
normal levels of IGF1 for their gestational age, slowed retinal 
development and poor vascularisation (Hellstrom et al., 
2001; Smith, 2005). This suggests that combined use of IGF1 
supplementation (to support vascular growth) together with 
anti-VEGF medication or laser treatment to treat 
neovascularisation (should it occur) might provide a 
beneficial treatment approach (Stahl et al., 2014). 
Disappointingly, a recent phase 2 trial - treating premature 
infants with recombinant IGF1 - could not demonstrate an 
effect on ROP, but showed an improvement in comorbidities 
of ROP (severe bronchopulmonary dysplasia and severe 
intraventricular haemorrhage) (Hellström et al., 2016). 
However, changes in national guidelines for oxygen 
saturation targets may have affected this trial (Hellström et 
al., 2016), and a subsequent phase 3 trial is planned. It is also 
possible that additional, human specific complexities need 
to be considered before the effects of IGF1 signalling 
modulation in mice can be translated into the clinic (Liegl et 
al., 2016), including parameters such as postnatal growth 
Fig. 7 Graphical summary of the major cell-cell interactions during retinal vascular development discussed in this review. Black arrows indicate 
direct ligand-receptor interactions (stippled in the case of hypothetical interaction), whereas grey arrows show indirect interactions (some of 
which are not entirely understood yet on a mechanistic level). Question marks indicate suspected but not yet confirmed influences. The ANG/TIE 
signalling system was not included here because its role in retinal vasculature development is not sufficiently understood yet. X: unknown astrocyte 
derived factor that is needed for primary plexus development, Y: receptor for factor X, MC: Müller cell, RGC: retinal ganglion cell, RA: retinal 




retardation and reduced bioenergetics, which are associated 
with ROP and low IGF1 levels (Hellström et al., 2010; Stahl et 
al., 2010a). In this context, it is interesting that nutritional 
influences such as dietary supplementation with omega 3 
polyunsaturated fatty acids can reduce pathology in mouse 
OIR (see section 6.1). Moreover, a recent human trial using 
fish-oil supplementation in low birth weight infants reduced 
the risk of ROP (Pawlik et al., 2014), demonstrating that 
manipulation of metabolism holds promising prospects for 
the future management of ROP.  
7. Conclusions and future directions 
Over the last two decades, a remarkably detailed 
understanding of the role of individual signalling pathways in 
retinal vascular development has emerged. Here we have 
discussed some of the key signals that mediate cell-cell 
interactions in this process (summarised in Fig. 7).  However, 
it has also become increasingly evident that many of these 
signalling pathways have more than one function in 
development. VEGF, for example, can act as a chemokine, a 
mitogen, or a survival factor for endothelial cells, depending 
on the location within the developing vascular plexus. 
Consequently, genetic mutations or pharmacological 
interventions targeting a specific pathway uniformly, often 
impact on vascular network development by perturbations 
on multiple levels, making the outcomes difficult to 
interpret. Thus, an emerging challenge is to dissect the 
functions of these signalling pathways (and their 
modulators) within defined morphogenetic modules, such as 
tip/stalk switching, lumen formation, sprout fusion, vessel 
pruning, regression and maturation. For this endeavour, 
inducible genetic tools and genetic mosaic analysis are 
promising approaches, with the potential to drive this field 
forward. Also, the development of novel in vitro models 
could facilitate progress in this area. Furthermore, zebrafish 
is already proving to be an immensely powerful in vivo model 
for research on the general principles of vascular 
development. Although insights gained in fish (or non-ocular 
mammalian vasculature) might not necessarily translate into 
the mammalian retina. Moreover, it is important to keep in 
mind that this limitation also applies in the reverse direction; 
i.e. findings made in the retina may not apply to the systemic 
vasculature, because the retinal vasculature has unique 
properties. For instance, the multiple feedback loops 
between retinal astrocytes and retinal vessels (see chapter 
3) may not have an equivalent in other vascular beds, and 
require caution when generalising experimental outcomes in 
retinal vasculature development. 
  
For the study of pathological retinal vasculature 
development, the mouse OIR model has been a key tool; 
providing a particularly good readout for excessive VEGF 
activity. It is less clear how far OIR represents human ROP 
beyond this readout; however, work in this model system 
has produced numerous candidate drug targets for ROP 
beyond VEGF (including many that are not mentioned in this 
review), several of which have entered - or are being 
developed towards - further testing in human clinical trials. 
ROP continues to be an important cause of childhood 
blindness, especially in middle-income countries where 
poorly controlled oxygen use is still common. In addition to 
improvements in neonatal care, effective screening 
guidelines and provision of medical supplies to monitor 
oxygen delivery, the development of novel therapeutic 
options in ROP remains a key objective to help curb the 
worldwide epidemic of this sight-threatening condition. 
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